U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2Cl.Zn
Molecular Weight 136.315
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Zinc chloride

SMILES

[Cl-].[Cl-].[Zn++]

InChI

InChIKey=JIAARYAFYJHUJI-UHFFFAOYSA-L
InChI=1S/2ClH.Zn/h2*1H;/q;;+2/p-2

HIDE SMILES / InChI

Description
Sources: http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783http://www.t3db.ca/toxins/T3D0733https://www.google.com/patents/US3130034https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.hmdb.ca/metabolites/HMDB01303http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttps://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459
Curator's Comment: description was created based on several sources, including http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicity

Zinc monocarbonate (Zinc Carbonate) is an inorganic salt. In the United States, Zinc Carbonate may be used as an active ingredient in OTC drug products. When used as an active drug ingredient, the established name is Zinc Carbonate. Zinc monocarbonate is generally recognized as safe by FDA. It is used as skin protectant active ingredient. Zinc carbonate was found to retard the degradation of some poly(lactide-co-glycolide) (PLG) microspheres in vivo and in vitro. Adding Zinc Carbonate is essential during the preparation of PLGA microspheres. It can remarkably improve the stability of drugs in the acid microenvironment inside PLGA microspheres.

CNS Activity

CNS Active
3913
Curator's Comment: Spatial memory deficits in a mouse model of late-onset Alzheimer's disease were caused by Zinc Carbonate supplementation. Long-term dietary administration of zinc ( Zinc Carbonate) can lead to impairments in cognitive function in rats. Microprobe synchrotron X-ray fluorescence (microSXRF) confirmed that brain zinc levels were increased by adding Zinc Carbonate to the drinking water.

Originator

Smithson, R.
38
Curator's Comment: Protherics that initially developed Voraxaze was acquired by BTG International in 2008. After the acquisition BTG International completed the development of Voraxaze and submitted the product for US approval.

Approval Year

1921
1467
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Activator
1430
Activator
1430
Hydrolytic Enzyme
38
ultraviolet B-induced damage
38
Target ID: ultraviolet B-induced damage
Interacts
323
Activator
1430
Zinc transporter ZIP1
38
Target ID: Q9NY26
Gene ID: 27173.0
Gene Symbol: SLC39A1
Target Organism: Homo sapiens (Human)
Binding Agent
1064
Zinc transporter ZIP2
38
Target ID: Q9NP94
Gene ID: 29986.0
Gene Symbol: SLC39A2
Target Organism: Homo sapiens (Human)
Binding Agent
1064
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Basic research
Unknown

Approved Use

Unknown
Primary
Approved
8429
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

1955
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Secondary
Approved
8429
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

2012
Primary
Approved
8429
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

2006
Primary
Approved
8429
ZINC OXIDE

Approved Use

Unknown
Primary
Approved
8429
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
Phase III
656
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
Phase III
656
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
PubMed

PubMed

TitleDatePubMed
A medicated polycarboxylate cement to prevent complications in composite resin therapy.
1990 Jan
Quadrupolar perturbed 14N NMR in the structurally commensurate and incommensurate phases of ammonium tetrachlorozincate.
1991 Apr 1
Molecular modeling studies suggest that zinc ions inhibit HIV-1 protease by binding at catalytic aspartates.
1993 Aug
Cupric ion blocks NF kappa B activation through inhibiting the signal-induced phosphorylation of I kappa B alpha.
1995 Nov 13
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus.
1997 Feb
Effects of trace metal compounds on HIV-1 reverse transcriptase: an in vitro study.
1999 May
Inhibition of HIV-1 infection by zinc group metal compounds.
1999 Sep
Combined effects of argon laser irradiation and fluoride treatments in prevention of caries-like lesion formation in enamel: an in vitro study.
1999 Spring
Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure.
2002 Mar 1
Comparison of the levels of copper, zinc and iron in cervical mucus and in blood serum of women of childbearing age.
2004
Lysine beta311 of protein geranylgeranyltransferase type I partially replaces magnesium.
2004 Jul 16
Inhibition by copper(II) binding of hepatocyte growth factor (HGF) interaction with its receptor Met and blockade of HGF/Met function.
2004 Jul 30
High-throughput computational and experimental techniques in structural genomics.
2004 Oct
Zinc-induced anti-apoptotic effects in SH-SY5Y neuroblastoma cells via the extracellular signal-regulated kinase 1/2.
2005 Apr 27
Effects of zinc supplementation in patients with type 1 diabetes.
2005 Summer
Characterization and inhibition of SARS-coronavirus main protease.
2006
Copper and zinc concentrations in serum of healthy Greek adults.
2006 Apr 15
Influence of dietary zinc and copper on digestive enzyme activity and intestinal morphology in weaned pigs.
2006 Dec
Elevated cortical zinc in Alzheimer disease.
2006 Jul 11
On the mechanism of the conversion of methanol to 2,2,3-trimethylbutane (triptane) over zinc iodide.
2006 Nov 10
Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles.
2007 May
Phosphorylation of p65 is required for zinc oxide nanoparticle-induced interleukin 8 expression in human bronchial epithelial cells.
2010 Jul
ZnO nanoparticles induce apoptosis in human dermal fibroblasts via p53 and p38 pathways.
2011 Dec
Responses of human cells to ZnO nanoparticles: a gene transcription study.
2011 Nov
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
Zinc oxide nanoparticles interfere with zinc ion homeostasis to cause cytotoxicity.
2012 Feb
Aerosolized ZnO nanoparticles induce toxicity in alveolar type II epithelial cells at the air-liquid interface.
2012 Feb
Association of zinc ion release and oxidative stress induced by intratracheal instillation of ZnO nanoparticles to rat lung.
2012 Jun 25
Distinct immunomodulatory effects of a panel of nanomaterials in human dermal fibroblasts.
2012 May 5
Additive effect of zinc oxide nanoparticles and isoorientin on apoptosis in human hepatoma cell line.
2014 Mar 3
Immunomodulatory activity of zinc peroxide (ZnO₂) and titanium dioxide (TiO₂) nanoparticles and their effects on DNA and protein integrity.
2014 May 16
Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition.
2014 May 16
Ultrasonic assisted removal of sunset yellow from aqueous solution by zinc hydroxide nanoparticle loaded activated carbon: Optimized experimental design.
2015
Synthesis aspects, structural, spectroscopic, antimicrobial and room temperature ferromagnetism of zinc iodide complex with Schiff based ligand.
2015 Jan 25
Effects of zinc fluoride on inhibiting dentin demineralization and collagen degradation in vitro: A comparison of various topical fluoride agents.
2016 Oct 1
Risk Assessment Study of Fluoride Salts: Probability-Impact Matrix of Renal and Hepatic Toxicity Markers.
2016 Sep
Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations.
2016 Sep 21
Intense 2.7μm emission in Er(3+) doped zinc fluoride glass.
2017 May 15
Patents

Patents

04005147
106
04090844
38
04134847
38
04292237
38
04376079
39
04377675
40
04404196
40
04565693
38
04670586
38
04740363
38
04743435
42
04904401
38
04950702
42
05064815
38
05149745
38
05442047
38
05539121
38
05646324
38
05773011
38
05911978
38
06140331
38
06303833
38
06706904
38
07375243
38
07585885
44
07799339
38
07959530
39
08258190
38
20060128799
38
20060270867
38
20070213331
40
20070249787
39
20080274173
38
20090092554
38
20100048844
38
20100117110
38
20100324259
38
7632959
38
CN105567322
38
EP0119068A1
38
US1767667
38
US20070265374
38
US2522537
38
US2537262
38
US3248354
38
US3453072
38
US3790469
38
US6853140
38

Sample Use Guides

In Vivo Use Guide
Rats: The dosage of zinc fluoride tetrahydrate (ZnF2 •4H2O) was adjusted to contain 2.1 mg (low-dose group, LG), 4.3 mg (mid-dose group, MG), and 5.4 mg fluoride per 200 g rat body weight (high-dose group, HG) corresponding to 5, 10, and 12.5 % of LD50 values for NaF.
Route of Administration: Oral
In Vitro Use Guide
Prepared ground human enamel specimens were immersed in zinc fluoride solutions containing 250 and 750 ppm F- at pH 6 and 4 for 4 min.
Name Type Language
Zinc chloride
EP   HSDB   II   INCI   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD  
INCI  
Official Name English
Zinc chloride [WHO-DD]
Common Name English
ZINC CHLORIDE [HSDB]
Common Name English
ZINCUM MURIATICUM
HPUS  
Common Name English
NSC-529648
Code English
ZINC CHLORIDE [EP IMPURITY]
Common Name English
ZINC CHLORIDE [MI]
Common Name English
ZINC CHLORIDE [EP MONOGRAPH]
Common Name English
ZINC CHLORIDE [USP MONOGRAPH]
Common Name English
ZINC CHLORIDE [INCI]
Common Name English
ZINC CHLORIDE [ORANGE BOOK]
Common Name English
ZINC CHLORIDE [MART.]
Common Name English
ZINC CHLORIDE [JAN]
Common Name English
ZINCUM MURIATICUM [HPUS]
Common Name English
ZINC CHLORIDE [II]
Common Name English
Classification Tree Code System Code
WHO-VATC QB05XA12
Created by admin on Fri Dec 15 15:31:51 GMT 2023 , Edited by admin on Fri Dec 15 15:31:51 GMT 2023
WHO-ATC B05XA12
Created by admin on Fri Dec 15 15:31:51 GMT 2023 , Edited by admin on Fri Dec 15 15:31:51 GMT 2023
EPA PESTICIDE CODE 87801
Created by admin on Fri Dec 15 15:31:51 GMT 2023 , Edited by admin on Fri Dec 15 15:31:51 GMT 2023
Code System Code Type Description
CHEBI
49976
Created by admin on Fri Dec 15 15:31:51 GMT 2023 , Edited by admin on Fri Dec 15 15:31:51 GMT 2023
PRIMARY
RXCUI
39937
Created by admin on Fri Dec 15 15:31:51 GMT 2023 , Edited by admin on Fri Dec 15 15:31:51 GMT 2023
PRIMARY RxNorm
DRUG BANK
DB14533
Created by admin on Fri Dec 15 15:31:51 GMT 2023 , Edited by admin on Fri Dec 15 15:31:51 GMT 2023
PRIMARY
NCI_THESAURUS
C29865
Created by admin on Fri Dec 15 15:31:51 GMT 2023 , Edited by admin on Fri Dec 15 15:31:51 GMT 2023
PRIMARY
SMS_ID
100000090232
Created by admin on Fri Dec 15 15:31:51 GMT 2023 , Edited by admin on Fri Dec 15 15:31:51 GMT 2023
PRIMARY
NCI_THESAURUS
C1505
Created by admin on Fri Dec 15 15:31:51 GMT 2023 , Edited by admin on Fri Dec 15 15:31:51 GMT 2023
CONCEPT Dietary Supplement
EPA CompTox
DTXSID2035013
Created by admin on Fri Dec 15 15:31:51 GMT 2023 , Edited by admin on Fri Dec 15 15:31:51 GMT 2023
PRIMARY
ECHA (EC/EINECS)
231-592-0
Created by admin on Fri Dec 15 15:31:51 GMT 2023 , Edited by admin on Fri Dec 15 15:31:51 GMT 2023
PRIMARY
RS_ITEM_NUM
1724736
Created by admin on Fri Dec 15 15:31:51 GMT 2023 , Edited by admin on Fri Dec 15 15:31:51 GMT 2023
PRIMARY
DAILYMED
86Q357L16B
Created by admin on Fri Dec 15 15:31:51 GMT 2023 , Edited by admin on Fri Dec 15 15:31:51 GMT 2023
PRIMARY
CAS
7646-85-7
Created by admin on Fri Dec 15 15:31:51 GMT 2023 , Edited by admin on Fri Dec 15 15:31:51 GMT 2023
PRIMARY
FDA UNII
86Q357L16B
Created by admin on Fri Dec 15 15:31:51 GMT 2023 , Edited by admin on Fri Dec 15 15:31:51 GMT 2023
PRIMARY
DRUG CENTRAL
4344
Created by admin on Fri Dec 15 15:31:51 GMT 2023 , Edited by admin on Fri Dec 15 15:31:51 GMT 2023
PRIMARY
HSDB
1050
Created by admin on Fri Dec 15 15:31:51 GMT 2023 , Edited by admin on Fri Dec 15 15:31:51 GMT 2023
PRIMARY
MESH
C016837
Created by admin on Fri Dec 15 15:31:51 GMT 2023 , Edited by admin on Fri Dec 15 15:31:51 GMT 2023
PRIMARY
ChEMBL
CHEMBL1200679
Created by admin on Fri Dec 15 15:31:51 GMT 2023 , Edited by admin on Fri Dec 15 15:31:51 GMT 2023
PRIMARY
NSC
529648
Created by admin on Fri Dec 15 15:31:51 GMT 2023 , Edited by admin on Fri Dec 15 15:31:51 GMT 2023
PRIMARY
PUBCHEM
5727
Created by admin on Fri Dec 15 15:31:51 GMT 2023 , Edited by admin on Fri Dec 15 15:31:51 GMT 2023
PRIMARY
EVMPD
SUB12622MIG
Created by admin on Fri Dec 15 15:31:51 GMT 2023 , Edited by admin on Fri Dec 15 15:31:51 GMT 2023
PRIMARY
MERCK INDEX
m11601
Created by admin on Fri Dec 15 15:31:51 GMT 2023 , Edited by admin on Fri Dec 15 15:31:51 GMT 2023
PRIMARY Merck Index
WIKIPEDIA
ZINC CHLORIDE
Created by admin on Fri Dec 15 15:31:51 GMT 2023 , Edited by admin on Fri Dec 15 15:31:51 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of ZINC CATION
SUBSTANCE RECORD
Structure of Zinc chloride
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966